---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-009491"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:09:30.084552+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Pieris restructures to capture partnered milestones; ends R&D, cuts workforce, cash $26.4M

## Summary
- As of Dec 31, 2023, cash and investments $26.4M; cost cuts expected to extend runway into 2027.
- All R&D activities to cease by mid-2024; additional workforce and board reductions planned in Q2 2024.
- Eligible for up to $75M in near-term milestones from Pfizer, Boston Pharmaceuticals, and Servier partnerships.
- Total potential milestones: up to $275M development and over $500M commercial across partnered 4-1BB bispecific programs.
- Company may pursue milestone/royalty monetization or cash dividends in future.

## SEC filing metadata
- accession: 0001437749-24-009491
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000143774924009491/0001437749-24-009491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000143774924009491/pirs20240323_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-009491
- JSON: https://secwatch.observer/filing/0001437749-24-009491.json
- Plain text: https://secwatch.observer/filing/0001437749-24-009491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.